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Abstract
Bacterial whole-genome sequencing in the clinical setting has the potential to bring major improvements to infection control
and clinical practice. Sequencing instruments are not currently available in the majority of routine microbiology laboratories
worldwide, but an alternative is to use external sequencing providers. To foster discussion around this we investigated
whether send-out services were a viable option. Four providers offering MiSeq sequencing were selected based on cost and
evaluated based on the service provided and sequence data quality. DNA was prepared from five methicillin-resistant
Staphylococcus aureus (MRSA) isolates, four of which were investigated during a previously published outbreak in the UK
together with a reference MRSA isolate (ST22 HO 5096 0412). Cost of sequencing per isolate ranged from £155 to £342 and
turnaround times from DNA postage to arrival of sequence data ranged from 12 to 63 days. Comparison of commercially
generated genomes against the original sequence data demonstrated very high concordance, with no more than one single
nucleotide polymorphism (SNP) difference on core genome mapping between the original sequences and the new sequence
for all four providers. Multilocus sequence type could not be assigned based on assembly for the two cheapest sequence
providers due to fragmented assemblies probably caused by a lower output of sequence data per isolate. Our results
indicate that external providers returned highly accurate genome data, but that improvements are required in turnaround
time to make this a viable option for use in clinical practice.
DATA SUMMARY
Genomes are deposited in the European Nucleotide Archive
under the accession numbers listed in Table S1 (available
in the online version of this article) (https://www.ebi.ac.uk/
ena).
INTRODUCTION
The utility of whole-genome sequencing (WGS) for accurately
identifying the population structure and genetic relatedness of
pathogenic bacteria has been demonstrated for a range of spe-
cies [1–4]. Associated with this is growing support for its
translation into diagnostic and public health microbiology,
including for the investigation of suspected outbreaks. This
could improve the accuracy of the current infection control
paradigm, in which suspected outbreaks are largely based on
epidemiological evaluation of two or more patients positive
for the same pathogen to determine whether an opportunity
for transmission could have occurred. However, this approach
has low sensitivity for transmission detection, probably
because patients can be cared for in several wards during the
same admission and outbreaks can span extensive time peri-
ods and multiple wards and even hospitals [1, 2]. When an
investigation suggests that an outbreak is likely, isolates may
be typed in-house or by a reference laboratory using a range
of methods that generally lack discrimination, may have a
long turnaround time and may not be comparable between
laboratories [3, 5, 6]. WGS has superior discriminatory power
compared to other typing techniques and its utility for the
investigation of clinical outbreaks has been confirmed [5, 7].
The generation of the entire genome also has the potential to
detect genes encoding antibiotic resistance and virulence
factors.
Sequencing instruments are not generally available in the
majority of routine microbiology laboratories. The cost (start-
up and running), space and expertise required to undertake
bacterial WGS to support routine infection control practice
are barriers to local implementation. An alternative would be
to use one of the increasing number of commercial WGS
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services available. The aim of the study was to compare a
selection of these WGS services for price, turnaround time,
ease of use and quality of returned data.
METHODS
Selecting commercial sequencing providers
In November 2016, we searched the internet for commercial
sequencing providers using ‘DNA sequencing’, ‘bacterial’
and ‘service’ as search terms. This resulted in the identifica-
tion of eight providers, who were contacted and quotes
requested for library preparation and paired-end whole
genome sequencing of five methicillin-resistant Staphylococ-
cus aureus (MRSA) isolates multiplexed in a single run on
an Illumina MiSeq instrument. Providers are referred to
here as A to H, details of which are shown in Table 1.
Bacterial isolates
The bacterial isolates used for the evaluation were four MRSA
isolates sequenced previously as part of an outbreak investiga-
tion on a Special Care Baby Unit (SCBU) [8], and the MRSA
reference isolate ST22 HO 5096 0412 (accession number
HE681097). Three of the four SCBU MRSA isolates [one each
from patient (P)14 (genome sequence accession number
ERR72246), P15 (accession number ERR108054) and P23
(accession number ERR72247)] were multilocus sequence
type ST2371 (a single locus variant of ST22), and were closely
related. P14 and P23 had zero single nucleotide polymorphism
(SNP) difference in the core genome, and P15 differed from
these by five SNPs and had lost an ermC plasmid. The fourth
SCBU isolate (accession number ERR131801, ST22) was more
distantly related and not considered to be part of the outbreak,
and is referred to here by the original isolate number
SASCBU35. Sequences for these isolates were originally gener-
ated using an Illumina MiSeq with 150 bp paired-end reads at
the Wellcome Sanger Institute. Their genetic relatedness was
assessed in the original study by mapping to the ST22 HO
5096 0412 reference using SMALT (http://www.sanger.ac.uk/
science/tools/smalt-0). The SNP calling parameters used were:
4 reads matching the SNP, minimum of 2 reads per strand;
required read support =0.8; reads must have greater than 90%
match to the reference to be mapped; and no removal of clus-
tered SNPs or genome masking.
DNA extraction and sequence data analysis
Stored isolates were plated onto Columbia blood agar
(Oxoid) and incubated for 24 h in air at 37

C. A single col-
ony was picked and sub-cultured onto Columbia blood agar
and incubated as before. Ten single colonies from each iso-
late were selected from the purity plate for DNA extraction
(ten DNA replicates per isolate). DNA was extracted using
the QIAmp mini DNA kit (Qiagen) and the ten replicates
for each isolate were then pooled. Aliquots of the pooled
samples were sent to each provider, with the exception of
provider D which required an EDTA-free elution after sam-
ple preparation. DNA quantity was measured using a Qubit
2.0 fluorometer (ThermoFisher Scientific). Adjustments
were made to the DNA concentration using DNAse-free
water to meet the input DNA requirements of each
IMPACT STATEMENT
Whole-genome sequencing is a highly discriminatory
method that can define the extent to which bacteria are
related. This has major potential for use in infection con-
trol and could enhance the accuracy of outbreak detec-
tion. One barrier to local implementation is the lack of
sequencing instruments in most routine microbiology
laboratories. An alternative is to use an external genome
sequencing provider. Here, we compared several
sequencing providers for price, turnaround time, ease of
use and quality of returned data. We found that external
providers returned highly accurate genome data, but that
improvements are required in turnaround time to make
this a viable option for use in clinical practice.
Table 1. Overview of whole-genome sequence providers
Sequence
provider
Country Cost per
sample (£)
Stated turnaround
time (days)
Actual turnaround
time (days)
Delivery method (as
requested)
Method of data return
B Mainland
Europe
155.58 21–35 29 Regular post, room
temperature
USB stick in post
C UK 338.16 7–14 12 Regular post, room
temperature
Link to Illumina
BaseSpace project
F UK 336.00 28–42 28 Courier, ice box Link to ftp site
D UK 342.00 56–70 63 Courier, ice box Link to secure company
website
E UK 612.00 21–28 Not applicable Not applicable Not applicable
H Mainland
Europe
836.00 28 Not applicable Not applicable Not applicable
A UK 900.00 Not provided Not applicable Not applicable Not applicable
G Asia Not available* Not applicable Not applicable Not applicable Not applicable
*Provider G did not provide a MiSeq service, only HiSeq services.
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provider, and samples were sent using the requested method
of delivery (Table 1).
Sequence data from each provider were downloaded from
either a user-accessed website (providers C, D and F) or a
USB-stick (provider B). The original sequence data for the
four clinical isolates (P14, P15, P23 and SASCBU35) and the
ST22 reference strain (HO 5096 0412) were downloaded from
the Sanger database and the European Nucleotide Archive
(ENA, http://www.ebi.ac.uk/ena/), respectively. Species identi-
fication was performed using Kraken [9]. All sequences were
assembled using Velvet [10] and annotated using Prokka [11].
The ST was identified using an in-house script (https://github.
com/sanger-pathogens/mlst_check) [12]. Multilocus sequence
type (MLST) alleles that could not be identified were investi-
gated further using BLAST. All sequences were mapped to the
ST22 reference strain using SMALT. SNPs were identified
using an in-house script (https://github.com/sanger-patho-
gens/snp-sites). The parameters used to call a SNP were as fol-
lows: 4 reads matching the SNP, minimum of 2 reads per
strand; required read support =0.75; no removal of clustered
SNPs or genome masking.
RESULTS
Service provision by commercial providers
We initially identified eight commercial providers and
obtained quotes for library preparation and whole genome
sequencing of five MRSA isolates on a single MiSeq run.
Quoted cost ranged from £155.58 to £900 per isolate. Pro-
viders with the four lowest quotes were selected for further
evaluation. Cost, DNA preparation, postage requirements,
turnaround time (from the day of postage/collection by cou-
rier) and data format are summarized in Table 1, which shows
variation in all of these parameters. The time between posting
the sample and receipt by the company was 1–2 days within
the UK (both regular post and courier) and 7 days for the ser-
vice based outside of the UK. The actual median (range) turn-
around time was 28.5 days (12–68 days). All companies
delivered the data within their pre-defined deadline. Provider
B was the cheapest (£155.58 per sample), whilst provider C
had the fastest turnaround time (12 days).
Sequence data metrics
All sequences were correctly assigned as S. aureus with greater
than 89% of the reads matching S. aureus (Table S1). How-
ever, the number of reads classified as other species (indicating
possible contamination) varied (Table S1), with provider B
having higher levels of putative contamination compared to
the others. Provider D indicated that the sequence data for
P14 were probably contaminated with Staphylococcus warneri,
which was consistent with findings from our informatic analy-
sis. We found that 0.11% of reads from isolate P14-provider
D mapped to this species compared to 0% of reads from other
companies.
Analysis of raw data and the results of assembly identified that
the four providers had used different read-lengths, ranging
from 150 bp (provider F) to 300 bp (provider B) (Table S1).
Sequence providers D and F produced more total raw bases
and, probably as a result of this, the assemblies from these two
providers had a lower number of contigs and a higher N50,
signifying a better assembly (Fig. 1). The total number of con-
tigs for the four isolates ranged from 34 to 337 (median 87.5),
with two outliers containing a much larger number of contigs
than the remainder (P23-provider C, 244 contigs; HO 5096
0412-provider B, 337 contigs) (Fig. 1). The lengths of the
assemblies were similar across providers, although provider F
produced consistently smaller assemblies and the assembly of
isolate SASCBU35-provider D was larger than the remainder
(2 903 570 bp versus the next largest at 2 857 410 bp). The
results are summarized in Table S1.
Sequence data analysis
STs were assigned from the sequence data. One allele could
not be assigned for P23 from provider C data (arcC) or for ref-
erence strain HO 5096 0412 from provider B data (aroE). The
BLAST analysis (https://blast.ncbi.nlm.nih.gov/Blast.cgi) dem-
onstrated that this was due to fragmentation of the locus
across contigs in both cases, which is consistent with the
higher contig number for these two specific isolates from these
providers. MRSA outbreak analysis is based on mapping of
the genome to a reference, and enumeration of SNPs between
test isolates. This was recapitulated for the newly generated
data for the four SCBU isolates (P14, P15, P23 and
SASCBU35) and reference isolate (HO 5096 0412), in which
these were mapped to the original HO 5096 0412 sequence
data and then compared with the original sequence for each
isolate. This demonstrated that five isolates from three pro-
viders had a single additional SNP (Fig. 2) [provider B (n=1),
D (n=3) and F (n=1)]. Reasons for these differences could be
heterogeneity in the selected colony or differences in the qual-
ity of the read data, such as the insert sizes. The insert sizes
(the length of the sequence between the adapters) for the data
from providers B, C and F were smaller than the combined
length of the forward and reverse reads (Table S1), meaning
that ~100–200 bp of the DNA fragments were sequenced
twice. This could improve the sequence quality at the ends of
the reads, where quality usually drops. However, a single SNP
difference would lead to no changes in the interpretation of
relatedness in the context of an outbreak.
DISCUSSION
Pathogen genome sequencing for applications such as out-
break investigation and the agnostic detecting of genes
encoding antibiotic resistance or virulence factors could
bring major improvements to infection control and clinical
practice. The availability of sequencing instruments in rou-
tine diagnostic microbiology laboratories is currently low,
and there are no providers to our knowledge that offer a
clinically accredited pathogen sequencing service to unaffili-
ated users. We investigated whether send-out services were
a viable option, focusing on the Illumina MiSeq instrument
based on its relatively short run time of around 24 h. Four
providers were selected from a total of eight based on cost
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and overall service turnaround time. Providers were blinded
to the study objectives.
The four providers returned sequence data within their
stated turnaround time, the actual time varying between 12
and 63 days. Although provider C out-performed the others
by at least 16 days, a 12 day turnaround plus the time taken
to isolate the organism and extract DNA represents a time-
scale that would be unlikely to provide information that
would have impact on clinical and infection control prac-
tice. This is because the longer the turnaround time, the
more likely it is that the outbreak will have spread further,
making it harder to control, and the more likely it is that
patients will have moved, for example, to care facilities or
the community. This movement may result in transmission
to other vulnerable patient populations and make it harder
to decolonize affected individuals. It remains possible that
the providers could offer a more rapid service, because they
were not given the option to offer an expedited service.
However, it is likely that a reduction in the turnaround time
from that stated by the provider would impact on the cost
per sample. In an ideal world the turnaround time for clini-
cal samples would be 24–48 h as this would allow clinicians
and infection control staff to rapidly identify individuals
involved in transmission and implement procedures to pre-
vent or halt an outbreak, as opposed to ‘playing catch-up’.
However, it is possible that turnaround times of less than
1 week may still have clinical value, particularly if an out-
break is centred on a ward or person.
The cost per sample identified in this study was ~£150 to
£900. We requested that the five study MRSA isolates be mul-
tiplexed and sequenced in a single run to minimize any delays
caused by batching samples from elsewhere. Costs could be
decreased by multiplexing more isolates on a single run
because the quotes were based on purchasing a whole run, in
addition to library prep reagents for each sample. This means
that the lowest cost provider may represent a viable option for
diagnostic laboratories in healthcare settings where reimburse-
ment is or could become available for pathogen sequencing.
Cost-effectiveness studies taking into account morbidity, mor-
tality and healthcare costs are now required to determine the
cost at which sequencing would be viable for clinical use based
on different clinical scenarios.
Whilst we selected a MiSeq for this study based on its short
turnaround time, the results may have differed if other
instruments or run requirements were allowed. Alternative
platforms available for WGS from commercial providers
were the Illumina HiSeq and NextSeq500, both of which
have longer run times than the MiSeq. Both platforms
sequence a higher number of samples per run and enquiries
into use of the HiSeq revealed that samples would need to
wait for a run to be filled, increasing the turnaround time.
Relaxing the run requirements to allow other samples to be
Fig. 1. Assembly statistics for sequences returned by the four sequence providers. Graphs showing genome sequence data quality for
five MRSA isolates sequenced by four sequence providers. (a) Total number of raw bases returned per isolate, (b) total length of the
assembly per isolate, (c) total number of contigs in the assembly per isolate and (d) N50 for the assembly of each isolate (the size of
the contig halfway along the assembly).
Raven et al., Microbial Genomics 2018;4
4
Downloaded from www.microbiologyresearch.org by
IP:  131.111.184.102
On: Wed, 20 Jun 2018 13:54:46
sequenced in the same run would probably have reduced
costs but would have increased the turnaround time.
All four providers returned data that were of sufficiently
high quality to perform further analyses. The two more
expensive providers generated more sequence data, which
resulted in the correct ST being assigned due to better
assemblies. However, analysis tools such as ARIBA can now
detect MLSTs from raw reads [13], meaning that STs could
be assigned despite fragmented assemblies. Whilst most
sequences were identical between providers, five isolates had
a single SNP compared to the reference. In a clinical out-
break scenario a single SNP would not change the interpre-
tation of whether two isolates were part of the same
outbreak, indicating data of sufficiently high quality for clin-
ical use.
In order for clinical laboratories to use a commercial pro-
vider, the WGS service would ideally need to become
accredited by the United Kingdom Accreditation Service.
This may be a viable option because some providers have
achieved accreditation for other services. However, in the
absence of this, validation by local clinical laboratories may
be a feasible alternative. Requirements for validation for
Public Health England laboratories are described in the ‘UK
Standards for Microbiology Investigations. Evaluations,
validations and verifications of diagnostic tests’ [14]
and include repeatability and reproducibility experiments,
analysis of the sensitivity and specificity, and use of control
strains.
An alternative option for clinical laboratories would be the
introduction of routine WGS into reference laboratories,
reducing the space and technical expertise required to run
the service. Reference laboratories currently offer tests such
as molecular typing, toxin gene detection and resistance
testing for S. aureus, and have recently begun performing
WGS for specific clinical samples: gastrointestinal diseases,
suspected outbreaks of importance and Mycobacterium
tuberculosis. However, results can take weeks to be returned
and, as with the providers tested in this study, this turn-
around time would need to be improved to allow outbreaks
to be investigated prospectively and results to be returned in
a clinically useful timeframe.
Conclusion
In summary, we have shown that external providers are a
possible option for diagnostic microbiology laboratories that
seek to undertake pathogen sequencing, but improvements
will be required in turnaround time. This service will also
require accreditation. An unresolved barrier is the availabil-
ity of software that performs automated interpretation and
provides information to users that can be understood by
those without informatics training. Further investigations of
the cost-effectiveness of pathogen sequencing are urgently
Fig. 2. SNPs in the sequences from providers B, C, D and F compared to the original sequence based on mapping to a reference. Left:
maximum-likelihood phylogeny of the sequences from each of the four external companies and the sequences from the original study
mapped to a reference strain. Labels indicate the isolate names, and colours highlight the five different isolates sequenced. Right:
graph indicating the number of SNPs between each sequence returned from the four companies and the corresponding sequence
from the original study based on mapping to a reference genome. Colours indicate the provider (orange=C, blue=B, grey=D, yellow=F),
and bars along the bottom indicate the four outbreak isolates sent for sequencing.
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required to support decisions to reimburse pathogen
sequencing costs.
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